Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859222 · ClinicalTrials.gov registry record · Phase 1
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
A Phase 1 study, sponsored by Patrick Y. Wen, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT00859222 is a Phase 1 study that has completed, run by Patrick Y. Wen, MD. The registered enrollment target is 51 participants.
The verdict
NCT00859222, a Phase 1 study, has completed, sponsored by Patrick Y. Wen, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor.
Interventions
- DRUG bevacizumab
- DRUG LBH589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2009-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00859222
The ClinicalTrials.gov registry entry for NCT00859222 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Patrick Y. Wen, MD, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT00859222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00859222 about?
NCT00859222 is a clinical study titled "LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma". The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone...
What is the current status of trial NCT00859222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2009-03. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00859222?
The interventions under investigation include: bevacizumab (DRUG), LBH589 (DRUG).
Who is sponsoring clinical trial NCT00859222?
This trial is sponsored by Patrick Y. Wen, MD, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.